NAMS Menopause Certification Exam – Questions and Answers
Actual Exam 2026/2027: Complete Exam-Style Questions with
Detailed Rationales | 100% Verified | Pass Guaranteed – A+
Graded
TABLE OF CONTENTS
Section 1 | Menopause Physiology and Diagnosis | Q1 – Q10
Section 2 | Hormone Therapy Options, Risks, and Benefits | Q11 – Q20
Section 3 | Nonhormonal Therapies and Lifestyle Management | Q21 – Q30
Section 4 | Long-term Health: Osteoporosis, Cardiovascular, and Cognition | Q31 – Q40
Section 5 | Patient Communication and Clinical Practice Integration | Q41 – Q50
Instructions: Choose the single best answer. Pass: 80% in 90 minutes.
══════════════════════════════════════
SECTION 1: MENOPAUSE PHYSIOLOGY AND DIAGNOSIS Q1 – Q10
══════════════════════════════════════
Question 1 of 50
A 51-year-old female presents to her gynecologist complaining of irregular menstrual
cycles over the past eight months, with cycles ranging from 21 to 45 days. She reports
occasional hot flashes that wake her at night and mild mood irritability. Her last Pap
smear was normal one year ago. Her FSH level is 28 mIU/mL. Which stage of
reproductive aging best describes her current status?
A. Late reproductive phase
B. Early menopausal transition ✓ CORRECT
C. Late menopausal transition
D. Postmenopause
Correct Answer: B
Rationale: The early menopausal transition is characterized by variable cycle length with
a difference of seven or more days between consecutive cycles, elevated but variable
,FSH levels, and emerging vasomotor symptoms. Option C, late menopausal transition, is
defined by amenorrhea of 60 days or longer and more pronounced FSH elevation above
40 mIU/mL. Recognizing the stages of reproductive aging helps clinicians counsel
patients about symptom trajectory and fertility potential, as unintended pregnancy
remains possible during the menopausal transition.
Question 2 of 50
A 48-year-old perimenopausal woman asks her nurse practitioner why she experiences
hot flashes and night sweats. The clinician explains that declining ovarian function
alters hypothalamic thermoregulation. Which neurotransmitter system is primarily
responsible for the thermoregulatory dysfunction that produces vasomotor symptoms?
A. Increased dopaminergic signaling in the preoptic area
B. Narrowing of the thermoregulatory zone due to decreased estrogen modulation of
kisspeptin-neurokinin B signaling ✓ CORRECT
C. Excessive serotonergic activity in the raphe nuclei
D. Enhanced gamma-aminobutyric acid inhibition of the hypothalamus
Correct Answer: B
Rationale: Declining estrogen disrupts the normal feedback on hypothalamic kisspeptin,
neurokinin B, and dynorphin neurons in the arcuate nucleus, narrowing the
thermoregulatory zone and causing inappropriate heat dissipation responses that
manifest as hot flashes. Option A incorrectly suggests dopamine excess, which is not
implicated in vasomotor symptom pathophysiology. Understanding the neurobiology of
hot flashes explains why both estrogen replacement and neurokinin-3 receptor
antagonists like fezolinetant can effectively treat vasomotor symptoms through
different mechanisms.
Question 3 of 50
,A 46-year-old woman presents with amenorrhea for four months. She reports hot
flashes, vaginal dryness, and difficulty sleeping. Laboratory studies show FSH 52
mIU/mL, LH 38 mIU/mL, and estradiol less than 20 pg/mL. She is concerned about
whether she needs contraception. What is the most accurate clinical guidance?
A. She should continue contraception for 12 months after her final menstrual period if
amenorrhea is confirmed
B. She should continue contraception until she has had 12 consecutive months of
amenorrhea to confirm menopause ✓ CORRECT
C. She no longer needs contraception because her FSH confirms ovarian failure
D. She should use contraception indefinitely due to her age
Correct Answer: B
Rationale: Menopause is clinically diagnosed retrospectively after 12 consecutive
months of amenorrhea, and elevated FSH alone does not confirm irreversible ovarian
failure during the menopausal transition when ovulation can still occur intermittently.
Option C is dangerous because pregnancy remains possible until menopause is
confirmed, and FSH levels fluctuate considerably during perimenopause. Counseling
perimenopausal women about ongoing contraceptive needs prevents unintended
pregnancies, which carry higher risks in this age group.
Question 4 of 50
A 44-year-old woman with a history of oligomenorrhea presents with acne, hirsutism,
and irregular periods. Her total testosterone is mildly elevated, and her AMH level is
higher than expected for her age. Her mother experienced menopause at age 52. Which
factor most likely explains why this patient may have a delayed onset of menopause
compared to her mother?
A. Her elevated testosterone directly stimulates ovarian follicular development
B. Higher AMH reflects a larger antral follicle pool, suggesting greater ovarian reserve
and potentially later menopause ✓ CORRECT
C. Hirsutism protects ovarian follicles from atresia
, D. Her acne indicates excess estrogen production that preserves ovarian function
Correct Answer: B
Rationale: Anti-Müllerian hormone is produced by granulosa cells of antral follicles and
serves as a biomarker of ovarian reserve; higher AMH correlates with a larger remaining
follicle pool and is associated with later age at menopause. Option A is incorrect
because testosterone does not stimulate follicular development in this context. AMH
measurement in midlife can help predict menopause timing and symptom severity,
though it is not routinely used for this purpose in clinical practice.
Question 5 of 50
A 53-year-old woman who had a hysterectomy at age 45 for fibroids presents wondering
if she is menopausal. She has no uterus and therefore cannot use menstrual history to
define menopause. She reports hot flashes, sleep disturbance, and vaginal dryness. Her
FSH is 65 mIU/mL. How should menopause be determined in this patient?
A. Menopause cannot be determined without a uterus
B. Menopause is diagnosed based on symptoms and elevated FSH in the absence of
menses, though confirmation may require serial testing ✓ CORRECT
C. Menopause is confirmed by a single FSH greater than 25 mIU/mL
D. Menopause requires bilateral oophorectomy to be diagnosed
Correct Answer: B
Rationale: In women without a uterus, menopause is diagnosed clinically based on
characteristic vasomotor and urogenital symptoms combined with elevated FSH,
though serial testing may be needed because FSH fluctuates during the transition.
Option A is incorrect because menopause can be determined without menstrual history,
and option C sets an inappropriately low FSH threshold. Clinicians must rely more
heavily on symptom assessment and laboratory trends in hysterectomized women, as
the retrospective 12-month amenorrhea criterion cannot be applied.
Actual Exam 2026/2027: Complete Exam-Style Questions with
Detailed Rationales | 100% Verified | Pass Guaranteed – A+
Graded
TABLE OF CONTENTS
Section 1 | Menopause Physiology and Diagnosis | Q1 – Q10
Section 2 | Hormone Therapy Options, Risks, and Benefits | Q11 – Q20
Section 3 | Nonhormonal Therapies and Lifestyle Management | Q21 – Q30
Section 4 | Long-term Health: Osteoporosis, Cardiovascular, and Cognition | Q31 – Q40
Section 5 | Patient Communication and Clinical Practice Integration | Q41 – Q50
Instructions: Choose the single best answer. Pass: 80% in 90 minutes.
══════════════════════════════════════
SECTION 1: MENOPAUSE PHYSIOLOGY AND DIAGNOSIS Q1 – Q10
══════════════════════════════════════
Question 1 of 50
A 51-year-old female presents to her gynecologist complaining of irregular menstrual
cycles over the past eight months, with cycles ranging from 21 to 45 days. She reports
occasional hot flashes that wake her at night and mild mood irritability. Her last Pap
smear was normal one year ago. Her FSH level is 28 mIU/mL. Which stage of
reproductive aging best describes her current status?
A. Late reproductive phase
B. Early menopausal transition ✓ CORRECT
C. Late menopausal transition
D. Postmenopause
Correct Answer: B
Rationale: The early menopausal transition is characterized by variable cycle length with
a difference of seven or more days between consecutive cycles, elevated but variable
,FSH levels, and emerging vasomotor symptoms. Option C, late menopausal transition, is
defined by amenorrhea of 60 days or longer and more pronounced FSH elevation above
40 mIU/mL. Recognizing the stages of reproductive aging helps clinicians counsel
patients about symptom trajectory and fertility potential, as unintended pregnancy
remains possible during the menopausal transition.
Question 2 of 50
A 48-year-old perimenopausal woman asks her nurse practitioner why she experiences
hot flashes and night sweats. The clinician explains that declining ovarian function
alters hypothalamic thermoregulation. Which neurotransmitter system is primarily
responsible for the thermoregulatory dysfunction that produces vasomotor symptoms?
A. Increased dopaminergic signaling in the preoptic area
B. Narrowing of the thermoregulatory zone due to decreased estrogen modulation of
kisspeptin-neurokinin B signaling ✓ CORRECT
C. Excessive serotonergic activity in the raphe nuclei
D. Enhanced gamma-aminobutyric acid inhibition of the hypothalamus
Correct Answer: B
Rationale: Declining estrogen disrupts the normal feedback on hypothalamic kisspeptin,
neurokinin B, and dynorphin neurons in the arcuate nucleus, narrowing the
thermoregulatory zone and causing inappropriate heat dissipation responses that
manifest as hot flashes. Option A incorrectly suggests dopamine excess, which is not
implicated in vasomotor symptom pathophysiology. Understanding the neurobiology of
hot flashes explains why both estrogen replacement and neurokinin-3 receptor
antagonists like fezolinetant can effectively treat vasomotor symptoms through
different mechanisms.
Question 3 of 50
,A 46-year-old woman presents with amenorrhea for four months. She reports hot
flashes, vaginal dryness, and difficulty sleeping. Laboratory studies show FSH 52
mIU/mL, LH 38 mIU/mL, and estradiol less than 20 pg/mL. She is concerned about
whether she needs contraception. What is the most accurate clinical guidance?
A. She should continue contraception for 12 months after her final menstrual period if
amenorrhea is confirmed
B. She should continue contraception until she has had 12 consecutive months of
amenorrhea to confirm menopause ✓ CORRECT
C. She no longer needs contraception because her FSH confirms ovarian failure
D. She should use contraception indefinitely due to her age
Correct Answer: B
Rationale: Menopause is clinically diagnosed retrospectively after 12 consecutive
months of amenorrhea, and elevated FSH alone does not confirm irreversible ovarian
failure during the menopausal transition when ovulation can still occur intermittently.
Option C is dangerous because pregnancy remains possible until menopause is
confirmed, and FSH levels fluctuate considerably during perimenopause. Counseling
perimenopausal women about ongoing contraceptive needs prevents unintended
pregnancies, which carry higher risks in this age group.
Question 4 of 50
A 44-year-old woman with a history of oligomenorrhea presents with acne, hirsutism,
and irregular periods. Her total testosterone is mildly elevated, and her AMH level is
higher than expected for her age. Her mother experienced menopause at age 52. Which
factor most likely explains why this patient may have a delayed onset of menopause
compared to her mother?
A. Her elevated testosterone directly stimulates ovarian follicular development
B. Higher AMH reflects a larger antral follicle pool, suggesting greater ovarian reserve
and potentially later menopause ✓ CORRECT
C. Hirsutism protects ovarian follicles from atresia
, D. Her acne indicates excess estrogen production that preserves ovarian function
Correct Answer: B
Rationale: Anti-Müllerian hormone is produced by granulosa cells of antral follicles and
serves as a biomarker of ovarian reserve; higher AMH correlates with a larger remaining
follicle pool and is associated with later age at menopause. Option A is incorrect
because testosterone does not stimulate follicular development in this context. AMH
measurement in midlife can help predict menopause timing and symptom severity,
though it is not routinely used for this purpose in clinical practice.
Question 5 of 50
A 53-year-old woman who had a hysterectomy at age 45 for fibroids presents wondering
if she is menopausal. She has no uterus and therefore cannot use menstrual history to
define menopause. She reports hot flashes, sleep disturbance, and vaginal dryness. Her
FSH is 65 mIU/mL. How should menopause be determined in this patient?
A. Menopause cannot be determined without a uterus
B. Menopause is diagnosed based on symptoms and elevated FSH in the absence of
menses, though confirmation may require serial testing ✓ CORRECT
C. Menopause is confirmed by a single FSH greater than 25 mIU/mL
D. Menopause requires bilateral oophorectomy to be diagnosed
Correct Answer: B
Rationale: In women without a uterus, menopause is diagnosed clinically based on
characteristic vasomotor and urogenital symptoms combined with elevated FSH,
though serial testing may be needed because FSH fluctuates during the transition.
Option A is incorrect because menopause can be determined without menstrual history,
and option C sets an inappropriately low FSH threshold. Clinicians must rely more
heavily on symptom assessment and laboratory trends in hysterectomized women, as
the retrospective 12-month amenorrhea criterion cannot be applied.
